AFQ056

DRUG20 trials

Sponsors

Novartis, Novartis Pharmaceuticals, Elizabeth Berry-Kravis

Conditions

Anti-Dyskinesia AgentsChoreaCocaine Use DisorderCocaine-related DisorderDyskinesia, Drug-InducedDyskinesiasFailed SSRI Over 12 Weeks at Appropriate DosesFragile X Syndrome

Phase 1

Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux

CompletedNCT00414856

NovartisGastroesophageal Reflux Disease

Start: 2006-08-31Target: 34Updated: 2007-06-22

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

CompletedNCT01442259

Novartis PharmaceuticalsMild Moderate, or Severe Renal Impairment

Start: 2011-01-31End: 2011-08-31Updated: 2020-12-08

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

CompletedNCT01456663

Novartis PharmaceuticalsHepatic Impairment

Start: 2011-05-31End: 2012-07-31Updated: 2020-12-08

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

CompletedNCT01482143

Novartis PharmaceuticalsFragile X Syndrome

Start: 2012-03-31End: 2013-10-31Updated: 2020-12-08

Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056

WithdrawnNCT04771143

Novartis PharmaceuticalsCocaine Use Disorder

Start: 2021-07-21End: 2022-01-03Updated: 2021-07-01

Phase 2

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

CompletedNCT00582673

NovartisParkinson's Disease

Start: 2007-10-31Updated: 2010-05-14

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

CompletedNCT00888004

NovartisL-dopa Induced Dyskinesia, Parkinson's Disease

Start: 2009-03-31Updated: 2016-04-19

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

CompletedNCT00986414

NovartisDyskinesias, Parkinson Disease

Start: 2009-09-30Target: 260Updated: 2017-02-23

Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

TerminatedNCT01019473

Novartis PharmaceuticalsChorea, Huntington's Disease

Start: 2009-11-30Updated: 2011-09-23

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

CompletedNCT01173731

Novartis PharmaceuticalsDyskinesia, Drug-Induced, Levodopa, Parkinson Disease

Start: 2010-10-31End: 2013-10-31Updated: 2020-12-23

Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome

CompletedNCT01253629

Novartis PharmaceuticalsFragile X Syndrome

Start: 2010-11-30End: 2013-08-31Updated: 2020-12-23

Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

TerminatedNCT01348087

Novartis PharmaceuticalsFragile X Syndrome

Start: 2011-08-31End: 2014-09-30Updated: 2016-05-25

Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

CompletedNCT01357239

Novartis PharmaceuticalsFragile X Syndrome

Start: 2011-05-31End: 2014-01-31Updated: 2015-05-12

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

CompletedNCT01385592

Novartis PharmaceuticalsDyskinesias, Movement Disorders, Parkinson Disease +1

Start: 2011-11-30End: 2012-09-30Updated: 2020-12-23

Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

TerminatedNCT01433354

Novartis PharmaceuticalsFragile X Syndrome

Start: 2011-11-30End: 2014-09-30Updated: 2016-03-24

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

CompletedNCT01491932

Novartis PharmaceuticalsAnti-Dyskinesia Agents, Dyskinesias, Movement Disorders +2

Start: 2012-03-31End: 2013-10-31Updated: 2020-12-23

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

CompletedNCT01491529

Novartis PharmaceuticalsAnti-Dyskinesia Agents, Dyskinesias, Movement Disorders +2

Start: 2012-04-30End: 2013-04-30Updated: 2020-12-23

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

TerminatedNCT01813019

Novartis PharmaceuticalsFailed SSRI Over 12 Weeks at Appropriate Doses, Patient Diagnosed With OCD and Resistant to SSRI Treatment

Start: 2013-11-30End: 2014-11-30Updated: 2017-01-02

AFQ056 for Language Learning in Children With FXS

CompletedNCT02920892

Elizabeth Berry-KravisFragile X Syndrome

Start: 2017-08-17End: 2022-05-17Updated: 2023-10-10

Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)

CompletedNCT03242928

Novartis PharmaceuticalsCocaine-related Disorder

Start: 2017-12-04End: 2019-12-16Updated: 2021-10-08

Related Papers

Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome.

2024-09-291 citations

Effects of AFQ056 on language learning in fragile X syndrome

Journal of Clinical Investigation2023-08-3115 citations

A telehealth approach to improving clinical trial access for infants with tuberous sclerosis complex.

2020-01-228 citations

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.

2017-01-0224 citations

Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study

Journal of Neurodevelopmental Disorders2015-12-1599 citations

A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.

2014-09-038 citations

Mavoglurant as a treatment for Parkinson's disease.

2014-06-2430 citations